10-Q: Dalrada Faces Going Concern Doubts Amidst Q2 Losses

Dalrada Technology Group reports a significant net loss and negative working capital, raising substantial doubt about its ability to continue as a going concern, despite some segment revenue growth.

Summary

• Dalrada Technology Group, Inc. reported a net loss of $10,487,650 for the six months ended December 31, 2025, an improvement from the $13,546,077 net loss in the prior year period.
• Total revenues decreased by 19.5% to $7,358,719 for the six months ended December 31, 2025, compared to $9,145,513 in the same period last year.
• The company's working capital deficit significantly worsened to $15,341,014 as of December 31, 2025, from $8,001,819 on June 30, 2025.
• Management has identified a material weakness in internal control over financial reporting, primarily related to preparing adequate and complete schedules across consolidated entities.
• Substantial doubt exists about the company's ability to continue as a going concern, dependent on successful financing and profitable subsidiary growth.
• Dalrada Climate Technology segment revenue increased by 52.8% to $3,012,653, driven by growth in residential development opportunities for Bothof Brothers Construction.
• Genefic segment revenue decreased by 43.4% to $3,508,387, attributed to limited working capital and a shift in sales pipelines.
• The company continues to rely heavily on related party financing, with related party notes payable increasing to $4,640,311 and accounts payable to related parties rising to $8,583,606 as of December 31, 2025.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the explicit going concern warning, severely deteriorating working capital, significant revenue decline, and identified material weakness in internal controls, despite a reduced net loss.

Positives

• Net loss for the six months ended December 31, 2025, improved to $10,487,650 from $13,546,077 in the prior year, indicating a reduction in losses.
• Dalrada Climate Technology segment experienced a significant revenue increase of 52.8% ($1,041,131) for the six months ended December 31, 2025, primarily due to growth in residential development opportunities for Bothof Brothers Construction.
• Dalrada Precision Manufacturing segment saw a substantial revenue increase of 539.2% ($116,107) for the three months ended December 31, 2025, driven by finalizing projects by Deposition Technology.
• Net cash used in operating activities decreased to $3,261,788 for the six months ended December 31, 2025, from $4,433,602 in the prior year, showing improved operational cash efficiency.

Negatives

• The company's total revenues decreased by 19.5% to $7,358,719 for the six months ended December 31, 2025, compared to $9,145,513 in the prior year.
• Genefic segment revenue decreased by 43.4% for the six months ended December 31, 2025, primarily due to limited working capital and a shift in sales pipelines.
• The working capital deficit significantly worsened to $15,341,014 as of December 31, 2025, from $8,001,819 on June 30, 2025.
• Cash and cash equivalents decreased to $70,074 as of December 31, 2025, from $172,787 as of June 30, 2025.
• Related party notes payable increased significantly to $4,640,311 as of December 31, 2025, from $1,701,415 as of June 30, 2025, indicating continued reliance on related party financing.
• Accounts payable and accrued liabilities to related parties increased by $2,621,130 to $8,583,606 as of December 31, 2025, primarily due to payroll-related expenditures.
• The company continues to incur significant losses and has limited working capital, raising substantial doubt about its ability to continue as a going concern.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for the twelve-month period following the report date, dependent on successful financing and profitable subsidiary growth.
• The company will be required to raise substantial capital to fund capital expenditures, working capital, and other cash requirements, with no assurance of obtaining additional financing on acceptable terms.
• A material weakness in internal control over financial reporting has been identified, related to preparing adequate and complete schedules across consolidated entities, which could lead to material misstatements.
• Ongoing legal proceedings, including breach of contract, fraud, and labor law violation lawsuits, pose potential financial liabilities and operational distractions.
• Increased costs are being incurred as a result of being a publicly traded company, including legal, accounting, and compliance expenses.

Future Outlook

Management anticipates needing additional liquidity over the next twelve months to fund operations, expand subsidiaries, grow pharmacies, commercialize DCT heat pump units, and expand Bothof Brothers Construction's development footprint. The company plans to support operations by raising capital and accelerating sales and marketing efforts for high-margin products and services. The continuation as a going concern is dependent on successful financing and generating profitable operations.

Management Comments

• "Our net loss and limited working capital raise substantial doubt about our ability to continue as a going concern."
• "We will continue to rely on related parties and seek other financing to complete our business plans."
• "Management is planning to support operations by raising capital, and by accelerating sales & marketing efforts of high-margin DCT heat pump units, precision parts, DepTecs deposition systems and COVID-19 testing."

Industry Context

StockSavvy.ai notes that Dalrada Technology Group operates across diverse sectors including healthcare, climate technology, precision manufacturing, and digital technologies. The mixed revenue performance across segments, with healthcare (Genefic) declining and climate technology growing, reflects the varied market dynamics and competitive pressures within each industry. The company's focus on 'sustainable, accessible, and affordable solutions' aligns with broader ESG trends, particularly in climate technology. However, the significant financial challenges and reliance on related party funding suggest a struggle to achieve sustainable growth and profitability across its broad portfolio, contrasting with more focused, well-capitalized players in these competitive industries.

Comparison to Industry Standards

• The company's substantial net loss and negative working capital are significantly below industry standards for healthy, growing technology and manufacturing companies, which typically aim for profitability and positive working capital.
• The reliance on related party debt and frequent revenue purchase agreements suggests a lack of access to traditional, more favorable financing options, which is atypical for established companies in the technology and manufacturing sectors.
• The identified material weakness in internal control over financial reporting is a serious concern, as robust internal controls are a fundamental standard for publicly traded companies, especially when compared to larger, more mature industry peers.
• While the 52.8% revenue growth in Dalrada Climate Technology is positive, it is offset by a 43.4% decline in the Genefic healthcare segment, indicating inconsistent performance across its diversified business units, unlike more specialized industry leaders who often show more uniform growth.

Corporate Governance

Legal Proceedings

• Asset Group, Inc. filed a breach of contract lawsuit against Dalrada Health Products (DHP) in September 2023, with DHP filing a cross-complaint for $3,240,000; a jury trial is scheduled for April 2026.
• A breach of contract lawsuit filed by MDIQ against DHTI in March 2024 has been settled and dismissed.
• DHTI filed a lawsuit against Simon Gray and DePrey Company in July for breach of contract and intentional interference with contractual relationships; discovery is ongoing.
• A lawsuit filed by DHTI in June 2024 against Stuart Cox (Likido acquisition) for fraud and breach of contract continues, with an amended complaint filed on January 29, 2026, after Cox's motion to vacate settlement was denied.
• DHTI filed a lawsuit in November 2024 against William Bonar, Samantha and Ian MacKenzie, Jillian Hughes, and Marion Bonar for fraud, tortious interference, and misappropriation of trade secrets; settlement discussions are ongoing, with an offer to return over 20,000,000 shares.
• A lawsuit filed by FFF Enterprises against Genefic, Inc. and DHTI in November 2024 for breach of a service agreement has been settled with no further liability.
• A former employee filed a complaint in June 2024 alleging labor law violations; a jury trial is scheduled for May 8, 2026, and settlement discussions are ongoing.
• Lamie RB Investments, LLC filed a suit for breach of a lease contract against Genefic, Inc. in March 2025; trial is scheduled for June 5, 2026, and settlement discussions are ongoing.
• A lawsuit filed by the Company against Wells Fargo in July 2025 has been settled and dismissed.
• Dalrada Precision Manufacturing Inc. filed a complaint in August 2025 against Global Resources Sustainability Group, LLC and Richard Abernathy for fraud, conversion, and breach of contract; a default has been filed against all parties.
• Cardinal Health filed a complaint in November 2025 against Genefic Specialty RX alleging non-payment of invoices; settlement discussions are ongoing.
• Former counsel to Dalrada filed a lawsuit in November 2025 for non-payment of attorney fees; settlement discussions are ongoing.

Related Party Transactions

• The company received cash funding or had expenses paid on its behalf by related parties, primarily for operational expenditures and payroll, leading to an increase in accounts payable to related parties.
• Accounts payable and accrued liabilities to related parties increased by $2,621,130 to $8,583,606 as of December 31, 2025.
• Related party notes payable (non-current portion) increased to $4,640,311 as of December 31, 2025, from $1,701,415 as of June 30, 2025.
• The company converted $11,861,578 of related party debt principal and interest into 14,205 shares of Series I Convertible Preferred Stock on June 25, 2025.
• A loan agreement was executed with Bandy Ranch Development, LLC (a related party) on October 1, 2025, for up to $250,000 to finance residential home construction.
• Bothof Brothers and Grand Entrances subsidiaries recognized revenues totaling $581,348 for the six months ended December 31, 2025, from corporations owned and/or operated by a related party.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity raises and the conversion of preferred stock and warrants.
• The 'going concern' doubt poses a substantial risk to the value of shareholder investments and the company's long-term viability.
• Employees may face uncertainty due to the company's financial instability and ongoing legal proceedings, including a labor law violation lawsuit.
• Creditors, particularly related parties, are heavily exposed given the significant increase in related party debt and accounts payable.
• Customers of Genefic may experience service disruptions due to limited working capital affecting revenue growth in that segment.
• The material weakness in internal controls could impact the reliability of financial reporting for all stakeholders.

Next Steps

• Management plans to raise additional capital through equity and/or debt investors.
• Accelerate sales and marketing efforts for high-margin DCT heat pump units, precision parts, DepTec's deposition systems, and COVID-19 testing.
• Continue efforts to collect outstanding accounts receivable from medical insurance providers.
• Remediation of the material weakness in internal control over financial reporting is expected to be substantially complete and fully tested by the end of the third quarter of fiscal 2026 (March 31, 2026).
• Jury trial scheduled for April 2026 in the Asset Group, Inc. vs. DHP legal proceeding.
• Jury trial scheduled for May 8, 2026, in the former employee labor law violation lawsuit.
• Trial scheduled for June 5, 2026, in the Lamie RB Investments, LLC vs. Genefic, Inc. lease contract dispute.

Key Dates

Recommendation

The filing presents a dire financial situation with a clear 'going concern' warning, a rapidly deteriorating working capital deficit, and declining revenues in key segments. The heavy reliance on related party financing and the identified material weakness in internal controls further compound the risks. While the net loss has decreased, the overall financial health is extremely poor, making the stock a high-risk investment with significant downside potential. The subsequent capital raises, while providing short-term liquidity, come with substantial costs and dilution, indicating ongoing financial distress rather than a path to sustainable profitability.

Keywords

Dalrada Technology Group, 10-Q, Quarterly Report, Financial Results, Net Loss, Working Capital Deficit, Going Concern, SEC Filing, Internal Controls, Related Party Transactions, Capital Raise, Healthcare Solutions, Climate Technology, Precision Manufacturing, Software Engineering